US EditionRoche to invest $50 billion in the U.S. as pharma tariff threat lingers
- Roche plans to invest $50 billion in the US over the next five years, focusing on pharmaceuticals and diagnostics amid tariff concerns.
- Roche employs over 25,000 people in the US and has 15 research and development centers as well as 13 manufacturing sites.
- Roche aims to build new R&D facilities and enhance production in California, Massachusetts, Indiana, and Pennsylvania.
- Once completed, Roche will export more medicines from the US than it imports.
146 Articles
146 Articles
From Campari to Louis Vuitton: The companies bowing to Trump and strengthening their US presence
The tariff war launched by U.S. President Donald Trump against the rest of the world has had numerous negative consequences for the world’s largest economy: widespread declines on Wall Street, a worrying deterioration in the U.S. debt market, a weakened dollar, a downgraded growth forecast by the IMF for this year, and retaliatory tariffs imposed by other countries. Seguir leyendo
Large pharmaceutical groups have begun to relocate their production to the United States, the world's leading drug market.
Mainstream Media Won't Tell You About the New Drug Factories
Do you know who our major trading partners are? The answer is Switzerland at number one, and Mexico at number two. Switzerland is the home of La Roche Pharmaceuticals. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. They plan to build more of their […] The post Mainstream Media Won’t Tell You About the New Drug Factories appeared first on www.independentsentinel.co…
Domestic and international companies like Apple, Nvidia, Hyundai, among others, will invest billions of dollars in factories and jobs in the US.
Coverage Details
Bias Distribution
- 45% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
